SUMITOMO PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 300 JPY | -0.66% |
|
-10.71% | -35.62% |
| May. 09 | Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd. | CI |
| May. 07 | Profit-Taking, China Outlooks Churn Asian Stock Markets | MT |
| Sales 2024 | 315B 2B | Sales 2025 * | 343B 2.18B | Capitalization | 119B 759M |
|---|---|---|---|---|---|
| Net income 2024 | -315B -2.01B | Net income 2025 * | -48.5B -309M | EV / Sales 2024 | 0.5 x |
| Net Debt 2024 * | 292B 1.86B | Net Debt 2025 * | 303B 1.93B | EV / Sales 2025 * | 1.23 x |
| P/E ratio 2024 |
-0.5
x | P/E ratio 2025 * |
-2.46
x | Employees | 6,250 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.26% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sumitomo Pharma Co., Ltd.
More recommendations
More press releases
| 1 day | -0.66% | ||
| 1 week | -10.71% | ||
| Current month | -24.81% | ||
| 1 month | -25.00% | ||
| 3 months | -14.04% | ||
| 6 months | -39.27% | ||
| Current year | -35.62% |
1 week
289.00
348.00
1 month
289.00438.00
Current year
289.00505.00
1 year
289.00693.00
3 years
289.002 363.00
5 years
289.002 391.00
10 years
289.004 135.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hiroshi Nomura
CEO | Chief Executive Officer | 66 | 05-09-30 |
Masayo Tada
CHM | Chairman | 79 | 05-09-30 |
Yoshiharu Ikeda
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Saeko Arai
BRD | Director/Board Member | 60 | 18-05-31 |
Nobuhiro Endo
BRD | Director/Board Member | 70 | 19-05-31 |
Masayo Tada
CHM | Chairman | 79 | 05-09-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 19 M€ | +9.76% | ||
| 0.15% | 64,792 M€ | +16.45% | ||
| 0.13% | 28,258 M€ | +16.51% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 300 | -0.66% | 4,210,300 |
| 24-05-23 | 302 | 0.00% | 7,256,800 |
| 24-05-22 | 302 | -2.27% | 6,805,700 |
| 24-05-21 | 309 | -8.85% | 8,615,300 |
| 24-05-20 | 339 | +0.89% | 4,239,000 |
Delayed Quote Japan Exchange, May 24, 2024 at 02:00 am EDT
More quotes
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).
Sector
Pharmaceuticals
Calendar
2024-07-28
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
300
JPY
Average target price
326.2
JPY
Spread / Average Target
+8.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.62% | 759M | |
| +38.51% | 727B | |
| +33.05% | 599B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +16.00% | 243B | |
| +8.09% | 205B | |
| -5.77% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 4506 Stock
